The whole answer, at its narrowest, in the first block
PT-141, also named bremelanotide, is one compound under two names. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Two published re-analyses dispute the size of the effect, and no approved use for men appears in the pack. This page restates fifteen claims the phrase invites, at the width the record carries, and recommends none.
Narrowest form: one compound, one approved indication, one defined population, nothing past it.
The sentence this whole site is holding
The record's sentence sits below, printed once and not paraphrased, with the qualifier that never leaves it.
The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose.
Four words carry the narrowing. Acquired holds the sentence to an acquired presentation. Generalized holds it to a generalized one. Premenopausal holds it to one defined population. Women holds it to that population and reaches no wider. Drop any one and the sentence has reported something the record does not say. The full disassembly runs on the approval sentence, word by word.
Narrowest form: four words hold the indication and the population, and the qualifier holds the rest.
Where the approval was read, and where it was not
The approval is carried by the supplier fact pack, read 2026-09-07, and by two published records read 2026-09-05. Those records state the approval and its one defined population. Neither is a copy of an approved label.
No approved-label document was fetched by either pack. This site names no regulator's document, links none, and builds no address for one. The two records are https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
Narrowest form: the approval is carried by the pack, the label document was not opened.
Fifteen claims this search arrives holding
[ five columns, scroll sideways to read a whole row ]
| What the search invites | The narrowest true form | What settles it | Where that was read | What it still does not settle |
|---|---|---|---|---|
| PT-141 is an approved medicine. | An approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. | An approved label noted in the pack | https://pubmed.ncbi.nlm.nih.gov/31429064/, https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | Whether anything a reader can reach carries that label. |
| The approval covers women. | The approval in the record covers premenopausal women with an acquired, generalized presentation, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. The pack holds no record reaching past that population. | An approved label noted in the pack | https://pubmed.ncbi.nlm.nih.gov/31429064/, read 2026-09-05 | Whether any record outside this pack addresses another population. |
| PT-141 is approved for men. | No approved use for men appears in the pack. The male material there is early-phase interventional work. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/, https://pubmed.ncbi.nlm.nih.gov/15833522/, read 2026-09-05 | Whether an approval for men exists in some record outside this pack. |
| PT-141 improves erectile function. | Two 2004 interventional records report an erectile response against placebo with direction improved, and a 2005 co-administration record enrolling nineteen participants reports the same direction. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/, https://pubmed.ncbi.nlm.nih.gov/15833522/, read 2026-09-05 | Size, durability, and anything at all about a person who was not in a trial. |
| PT-141 is well tolerated. | One integrated safety analysis across the development programme reports adverse events mostly mild to moderate, with nausea, flushing and headache more frequent than placebo, and rare focal hyperpigmentation. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | Anything about material outside that development programme. |
| PT-141 is hard on blood pressure. | The same analysis reports small, transient, statistically significant blood pressure increases, and it advises caution in patients at risk of cardiovascular disease. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, read 2026-09-05 | What happens to any individual, which a group result never reports. |
| Nausea is the thing to expect. | The integrated analysis reports nausea more frequent than placebo. One completed phase 1 record was registered to measure the rate of nausea in healthy premenopausal female subjects, and the pack reports no result from it. | A human interventional record | https://pubmed.ncbi.nlm.nih.gov/35147466/, https://clinicaltrials.gov/study/NCT03973047, read 2026-09-05 | A rate, because the pack carries none. |
| The phase 3 result is settled. | Two published re-analyses dispute it. One reports that most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The second reports effect sizes from nil to small on outcomes it judges to have questionable validity. | A review | https://pubmed.ncbi.nlm.nih.gov/33678061/, https://pubmed.ncbi.nlm.nih.gov/36809187/, read 2026-09-05 | Whether the approval was correctly granted. A re-analysis is not a regulator's finding. |
| PT-141 and bremelanotide are two different compounds. | One compound under two names, used interchangeably throughout the record. | A review | https://pubmed.ncbi.nlm.nih.gov/31429064/, read 2026-09-05 | What is inside anything sold under either name. |
| A meta-analysis has ranked the options. | The pack carries a 2026 systematic review and meta-analysis of treatments for female desire, arousal and orgasmic dysfunction, recorded by scope only. The pack carries no result from it. | A review | https://pubmed.ncbi.nlm.nih.gov/40543759/, read 2026-09-05 | Any comparison or ordering, because the pack records what the review covers and not what it found. |
| PT-141 is a weight compound. | One registered phase 2 study gives it together with a second agent for the treatment of obesity. It is active and not recruiting, and the pack reports no result. | A registered study with no result | https://clinicaltrials.gov/study/NCT06565611, read 2026-09-05 | Every outcome. A registration reports that a study exists. |
| PT-141 is studied for kidney disease. | One completed phase 2b open-label registered study in diabetic kidney disease. The pack reports no result. | A registered study with no result | https://clinicaltrials.gov/study/NCT05709444, read 2026-09-05 | Any outcome, and whether a result was published somewhere this programme did not read. |
| There is a label I can open and read. | No approved-label document was fetched by either pack. This site links none and builds no address for one. | Nothing | absent | Whether such a document is published. This programme did not open one, so it says nothing about it. |
| PT-141 is banned in sport, or is scheduled. | No record in either pack addresses sporting eligibility or legal scheduling for this compound. | Nothing | absent | The actual status, which is not readable from anything this programme fetched. |
| What is listed as research material is the approved product. | Neither pack contains a record connecting a research-grade listing to an approved label. | Nothing | absent | What any listing holds, which no record here reports. |
Rows order on the third column, in the sequence an approved label, a human interventional record, a review, a registered study with no result, nothing, then by how commonly the claim is arrived with. Position is not importance, and no planning number touches the order.
Column two is the whole product of this site, and everything else in the table exists to show where column two came from and what it declines to reach.
A row whose column three reads nothing is not a weak row. It is the most useful row on the page, the only place a reader is told outright that a claim they arrived holding has no record here.
Narrowest form: fifteen claims arrive, and column two is all the site actually says.
The disputes, printed beside the approval and not behind it
Two published re-analyses sit beside the approval, not behind it. The 2021 re-analysis reports that most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The 2024 re-analysis reports effect sizes from nil to small on outcomes it judges to have questionable validity.
Then the boundary that keeps the block honest in both directions. A re-analysis disputes the size of an effect. It is not a regulator's finding, and nothing here says the approval was wrongly granted. The two re-analyses run in full on the two re-analyses. Citations: https://pubmed.ncbi.nlm.nih.gov/33678061/ and https://pubmed.ncbi.nlm.nih.gov/36809187/.
Narrowest form: two re-analyses dispute a size, not the approval.
What the male records report, and the sentence that stops there
Three early interventional records report on men, all before the approval. Two 2004 records report an erectile response against placebo with direction improved, one in healthy males and men with mild to moderate erectile dysfunction, the other in healthy males and in men whose response to an existing treatment was inadequate. A 2005 co-administration record enrolling nineteen participants reports the same direction.
Then the narrowing. Early-phase work reports a direction in a group. No approved use for men appears in the pack, and the second agent goes unnamed. This runs in full on what the male records report. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
Narrowest form: three early records in men, and no approved use for men in the pack.
What the safety analysis reports, said once and not softened
The integrated analysis reports at its own width. Adverse events were mostly mild to moderate, with nausea, flushing and headache more frequent than placebo, rare focal hyperpigmentation, and small transient blood pressure increases.
Then two boundaries. The analysis advises caution in patients at risk of cardiovascular disease, and this page reports that the analysis carries that advice rather than carrying it. A group result reports nothing about an individual. This runs in full on what the safety analysis reports. Citation: https://pubmed.ncbi.nlm.nih.gov/35147466/.
Narrowest form: one analysis, reported as a report, its caution left as the record's.
What a registration reports
Nine registered records sit in the pack. Two completed phase 3 records and one completed phase 2 record are registered in premenopausal women, and one further completed phase 2 record is registered in women. Five others include a study of co-administration with a second agent for the treatment of obesity, active and not recruiting, and a completed phase 2b study in diabetic kidney disease.
The pack reports no result from any of them, and one line closes it. A registration reports that a study exists. The nine run in full on nine registered records. Citations: https://clinicaltrials.gov/study/NCT06565611 and https://clinicaltrials.gov/study/NCT05709444.
Narrowest form: nine registrations, and a registration reports only that a study exists.
One lot, and the rule that keeps a figure honest
Peptara Labs publishes one lot for this compound on its own front page. The row below reproduces it as published and generalises to nothing.
[ seven columns, scroll sideways to read a whole row ]
| Lot | Method | Purity as published | Certificate | Tested | Laboratory named | Where this was read |
|---|---|---|---|---|---|---|
| PT1-260411-A | HPLC | 99.12 percent | COA-2026-7459 | June 2026 | Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited | peptaralabs.io front page, read 2026-09-07 |
The figure, the lot and the certificate identifier travel together or none is published. No brand-wide average, no figure for a lot outside the supplier's published list, no compression of this row into a sentence about the compound. The release criterion of not less than 95.0 percent sits beside the figure so the number is not read bare.
The row settles three things and no more. It describes one lot on one date. No certificate document for this compound was opened here, so it is described as published and linked at the certificate index, never as read. No report from a second outside laboratory covers this compound.
The rule behind this figure runs in full at one lot, one certificate identifier.
Narrowest form: one figure, one lot, one certificate, and no reach past them.
How a claim gets narrowed here
The method is mechanical. The third column takes one of five values and never a sixth. The fifth column is written last and is never left blank. Rows sort on the third column, and where a row lands is not a judgement.
The full method, including why a row that reads nothing is kept, runs on how a claim gets narrowed here, and what the payment covers runs on what the payment covers.
Narrowest form: five values, a last column always filled, a mechanical sort.
Scope and research use
The work here is reading. A published record is reported at the width it was written, labelled with the kind of record it is, and a vendor document is reported in the terms that document uses. Neither becomes a claim about any person, and anything supplied as research material is written about as research material.
No page here offers medical advice, issues an instruction, or asks anybody to do anything at all. This is the one place in plain sight where the site says it: it publishes no instructions at all.
Narrowest form: reading only, no instruction, no claim about a person.
Questions this page is asked
Is PT-141 FDA approved?
Yes, and the narrow form is the whole answer. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. This site opened no regulator's document, names none and links none. Citations: https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: the approval sentence, word by word
What exactly does the PT-141 approval cover?
The approval whole, then its four narrowing words. The record states an approval in the United States for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and an approved label covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. Acquired. Generalized. Premenopausal. Women. None is glossed here, because neither pack defines these terms, and removing any one reports something the record does not say. Nothing here describes what the compound does for anyone. Citation: https://pubmed.ncbi.nlm.nih.gov/31429064/.
More: the approval sentence, word by word
Is PT-141 approved for men?
No approved use for men appears in the pack, and that is the exact shape of the answer, an absence in a named pack rather than a claim about the world. The male material there is early-phase interventional work: two 2004 records and one 2005 record, each reporting a direction on an erectile response endpoint, the 2005 one enrolling nineteen participants. Nothing is said about what a reader would experience. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
More: what the male records report
What do the male PT-141 studies actually report?
Three records, each named by year, model type and endpoint. Two 2004 randomized interventional records report an erectile response and tolerability against placebo, one in healthy males and men with mild to moderate erectile dysfunction, the other in healthy males and in men whose response to an existing treatment was inadequate. A 2005 randomized record reports an erectile response for the compound given together with a second agent, against that agent alone, in nineteen men. The second agent goes unnamed here. The answer closes on the limits the records carry themselves: small numbers, early phase, group directions. Citations: https://pubmed.ncbi.nlm.nih.gov/14963471/, https://pubmed.ncbi.nlm.nih.gov/14999221/ and https://pubmed.ncbi.nlm.nih.gov/15833522/.
More: what the male records report
Is PT-141 the same thing as bremelanotide?
Yes. One compound, two names, used interchangeably across the record, the approval stated under the second and much of the early work published under the first. A shared name settles what a record is about and nothing about what any seller ships under either. Citation: https://pubmed.ncbi.nlm.nih.gov/31429064/.
More: the approval sentence, word by word
What does the published safety review say about PT-141?
One integrated safety analysis across the development programme reports adverse events mostly mild to moderate, with nausea, flushing and headache more frequent than placebo, rare focal hyperpigmentation, and small transient statistically significant blood pressure increases. It advises caution in patients at risk of cardiovascular disease. The analysis carries that advice and this site does not, and a group result reports nothing about an individual. Citation: https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: what the safety analysis reports
Do researchers agree that PT-141 works?
Not on the size of it. The 2021 re-analysis reports most outcomes listed in the study plans went unreported, with substantially higher discontinuation from adverse events and a participant preference for placebo. The 2024 one reports effect sizes from nil to small on outcomes it judges to have questionable validity. A re-analysis disputes a size, it is not a regulator's finding, and no record in either pack reports the approval was wrongly granted. Citations: https://pubmed.ncbi.nlm.nih.gov/33678061/ and https://pubmed.ncbi.nlm.nih.gov/36809187/.
More: the two re-analyses
Is PT-141 being studied for anything besides sexual desire?
Yes, and every one exists here only as a registration. One phase 2 study of co-administration with a second agent for the treatment of obesity, active and not recruiting. One completed phase 2b open-label study in diabetic kidney disease. The pack reports no result from either, and a registration reports that a study exists and nothing else. Citations: https://clinicaltrials.gov/study/NCT06565611 and https://clinicaltrials.gov/study/NCT05709444.
More: nine registered records
What purity figure is published for PT-141, and what is it attached to?
One figure, attached to one lot. The supplier publishes lot PT1-260411-A at an HPLC purity of 99.12 percent under certificate COA-2026-7459, tested June 2026, on a panel run by Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The release criterion is not less than 95.0 percent. The figure never appears without its lot and its certificate identifier and is never averaged into a brand-wide number. No certificate document for this compound was opened here, so it is described as published and linked. Citations: https://peptaralabs.io/ and https://peptaralabs.io/coa.
More: one lot, one certificate identifier
Does a published certificate mean PT-141 is approved for anything?
No, and the two are not connected at any point. A certificate is a laboratory record of what one lot measured on named methods on a named date. It is not a permission and it describes no use. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. The supplier's own position, in this site's words: material graded for research plus writing that explains it, from an operation that treats nobody, identifies no condition, writes no prescription, watches over no one's care, promises no result, and stands no approved drug behind what it ships. Citations: https://peptaralabs.io/coa and https://peptaralabs.io/trust.
More: one lot, one certificate identifier
Where can I read the PT-141 label?
Not from here, and the answer says why in its first sentence rather than its last. No approved-label document was fetched by either pack, and no verified label address, database record or regulator's page for this compound exists in any fetch log available to this site, so it publishes no label link, names no regulator's document, and assembles no address that merely looks plausible. It names the two published records that state the approval instead. No substitute and no suggestion about where else to look, because pointing at a destination this site never opened is the same error wearing a helpful tone. Citations: https://pubmed.ncbi.nlm.nih.gov/31429064/ and https://pubmed.ncbi.nlm.nih.gov/35147466/.
More: how a claim gets narrowed here
What is Peptara Labs, and what does it publish?
Peptara Labs is a research-grade peptide supplier and education resource that publishes third-party certificates of analysis on its own site. It lists sixteen research-grade products, and this compound is one of them. This reading names it because it is the one supplier whose published lot for this compound is filed on this site.
Who tests the peptides Peptara Labs sells?
Titreon Analytical, described on the live page as a third-party laboratory whose quality system is aligned to ISO/IEC 17025:2017, not itself accredited. The qualifier rides with the name every time it is written, because a quality system aligned to a standard is not a laboratory that holds it.
Is Peptara Labs the source of an approved PT-141 product?
No. Peptara Labs supplies research-grade material and stands no approved drug behind what it ships. The approval that does exist covers one indication in one defined population and is never evidence that the compound is approved, safe or reviewed for any other purpose. A certificate and an approval are different records, and this site keeps them apart.
Narrowest form: eleven readings and three supplier notes, none of them an instruction.